Dario Eklund, Santhera Pharmaceuticals CEO
Santhera's clinical data are in, but NDA delayed 4-6 months by third party manufacturer
Santhera Pharmaceuticals finished submitting the clinical portion of its rolling NDA yesterday, but the Swiss biotech’s regulatory ambitions are now pushed back four to six …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.